Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood (2023) 142 (26): 2327–2331.

https://doi.org/10.1182/blood.2023021274

Published: 2023

Includes: Supplemental data

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

The Relapse-to-Therapy Interval in Relapsed or Refractory Diffuse Large B Cell Lymphoma Is Associated with Clinical Outcomes

Paolo F. Caimi, Christine Auberle, Krishna Goparaju, Molly Megan Gallogly, Firas Baidoun, Amanda F Cashen, Brian T. Hill

Blood (2023) 142 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2023-181274

Published: 2023

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Journal Articles

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Amneet K Bajwa, Qiuhong Zhao, Marcus Johannes Geer, Agrima Mian, Chenyu Lin, David Frame, James Westholder, Justin Tossey, Monalisa Ghosh, Ahmed Galal, Nausheen Ahmed, Joseph E. Maakaron, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo F. Caimi, Timothy Voorhees

Blood (2023) 142 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2023-179620

Published: 2023

Journal Articles

Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy

Merve Kacar, Robert M. Dean, Allison Winter, Brad Pohlman, Deepa Jagadeesh, Brian T. Hill, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 6198.

https://doi.org/10.1182/blood-2023-190885

Published: 2023

Journal Articles

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2023-182204

Published: 2023

Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2023-173943

Published: 2023

Journal Articles

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial

Mazyar Shadman, Paolo F. Caimi, Susan M. O'Brien, Patrick M. Reagan, Bruce Dezube, Punya Navaratnarajah, Tripti Gaur, Suzanne Petrossian, Anthony Germani, Brian G Till, Jeremy S. Abramson

Blood (2023) 142 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2023-175007

Published: 2023

Journal Articles

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Brenda W Cooper, Molly Megan Gallogly, Leland Metheny, Rebecca B. Klisovic, Kirsten Marie Boughan, Jane Reese Koc, Darong Wu, Changchun Deng, Koen Van Besien, Rose Tupta, Dina Schneider, Lisa Ciarrone, Marcos de Lima, Paolo F. Caimi, Benjamin K. Tomlinson

Blood (2023) 142 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2023-191153

Published: 2023

Journal Articles

Outcomes and Characteristics of Untreated Diffuse Large B-Cell Lymphoma (DLBCL) Patients: A SEER-Medicare Database Analysis

Akiva Diamond, Wyatt P. Bensken, Long Vu, Siran M. Koroukian, Paolo F. Caimi

Blood (2022) 140 (Supplement 1): 10979–10980.

https://doi.org/10.1182/blood-2022-170446

Published: 2022

Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Blood (2022) 140 (Supplement 1): 3673–3677.

https://doi.org/10.1182/blood-2022-157583

Published: 2022

Journal Articles

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

Seema Patel, Danielle Cenin, Donna Corrigan, Betty K. Hamilton, Matt Kalaycio, Ronald M. Sobecks, Faiz Anwer, Jack Khouri, Robert M. Dean, Allison Winter, Deepa Jagadeesh, Brad Pohlman, Brian T. Hill, Craig S. Sauter, Paolo F. Caimi

Blood (2022) 140 (Supplement 1): 5073–5074.

https://doi.org/10.1182/blood-2022-169809

Published: 2022

Journal Articles

Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Patterns and Outcomes in the Oldest-Old (≥85 years): A SEER-Medicare Database Analysis

Akiva Diamond, Wyatt P. Bensken, Long Vu, Siran M. Koroukian, Paolo F. Caimi

Blood (2022) 140 (Supplement 1): 8061–8062.

https://doi.org/10.1182/blood-2022-170521

Published: 2022

Journal Articles

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Blood (2022) 140 (Supplement 1): 186–188.

https://doi.org/10.1182/blood-2022-170381

Published: 2022

Journal Articles

Cell Product Differences on Incidence of Venous Thromboembolism in Patients Treated with CAR T-Cells for Aggressive B-Cell Lymphomas

Taylor Brooks, Agrima Mian, Betty K. Hamilton, Robert M. Dean, Allison Winter, Deepa Jagadeesh, Craig S. Sauter, Brian T. Hill, Paolo F Caimi

Blood (2022) 140 (Supplement 1): 12773–12774.

https://doi.org/10.1182/blood-2022-170350

Published: 2022

Journal Articles

Incidence of Secondary Hematological Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: An Analysis of SEER Database

Rahul Mishra, Agrima Mian, Shiva Jashwanth Gaddam, Paolo F Caimi, Deepa Jagadeesh

Blood (2022) 140 (Supplement 1): 9902–9903.

https://doi.org/10.1182/blood-2022-170269

Published: 2022

Journal Articles

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni

Blood (2022) 140 (Supplement 1): 9548–9550.

https://doi.org/10.1182/blood-2022-159626

Published: 2022

Journal Articles

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Blood (2022) 140 (Supplement 1): 10391–10393.

https://doi.org/10.1182/blood-2022-159725

Published: 2022

NARROW

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

The Relapse-to-Therapy Interval in Relapsed or Refractory Diffuse Large B Cell Lymphoma Is Associated with Clinical Outcomes

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Outcomes and Characteristics of Untreated Diffuse Large B-Cell Lymphoma (DLBCL) Patients: A SEER-Medicare Database Analysis

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Patterns and Outcomes in the Oldest-Old (≥85 years): A SEER-Medicare Database Analysis

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Cell Product Differences on Incidence of Venous Thromboembolism in Patients Treated with CAR T-Cells for Aggressive B-Cell Lymphomas

Incidence of Secondary Hematological Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: An Analysis of SEER Database

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only